dupilumab
regeneron,sanofi
['dupixent', 'dupilumab', '$regn']
$regn new article : dupixent (dupilumab) late-breaking phase 3 data at the eadv 2022 congress showed significant improvements in signs and symptoms of prurigo nodularis get all the latest $regn related news here : 
We’ll make staying up-to-date on top of your investments easy for you. Create a free account and get real-time financial news updates for your portfolio!